Downloads
Revenue

Description

Chimeric Antigen Receptor T-Cell Therapy (CAR T-cell Therapy) is a treatment in which a patient’s own blood cells are genetically reprogrammed to find and kill cancer cells.
Using your smartphone, tablet, or other handheld device, download our interactive mobile app to learn about the process of CAR T-cell therapy. Our 3-D animation illustrates how T cells and CAR T cells travel through the bloodstream to seek out and eliminate blood cancer cells.
Hide Show More...

Screenshots

LLS CAR T FAQ

  • Is LLS CAR T free?

    Yes, LLS CAR T is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is LLS CAR T legit?

    Not enough reviews to make a reliable assessment. The app needs more user feedback.

    Thanks for the vote

  • How much does LLS CAR T cost?

    LLS CAR T is free.

  • What is LLS CAR T revenue?

    To get estimated revenue of LLS CAR T app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating
App is not rated in Mexico yet.
Ratings History

LLS CAR T Reviews

No Reviews in Mexico
App doesn't have any reviews in Mexico yet.

Store Rankings

Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet

LLS CAR T Installs

Last 30 days

LLS CAR T Revenue

Last 30 days

LLS CAR T Revenue and Downloads

Gain valuable insights into LLS CAR T performance with our analytics.
Sign up now to access downloads, revenue, and more.

App Info

Category
Medical
Languages
English
Recent release
1.0 (4 years ago )
Released on
Jul 6, 2020 (4 years ago )
Last Updated
3 months ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.